Literature DB >> 10643627

Influence of pharmacological agents on portal hemodynamics: basis for its use in the treatment of portal hypertension.

J C García-Pagán1, A Escorsell, E Moitinho, J Bosch.   

Abstract

Progress in the knowledge of the pathophysiology of portal hypertension has opened the door to pharmacological treatments, resulting in a dramatic change in the therapeutic approach to portal hypertension. This review summarizes pharmacological agents that have been shown to effectively decrease portal pressure, paying special attention to its mechanisms of action. In addition, the way to monitor response and clinical efficacy of pharmacological agents is reviewed.

Entities:  

Mesh：

Year:  1999        PMID： 10643627     DOI： 10.1055/s-2007-1007130

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN： 0272-8087            Impact factor:   6.115


  13 in total

1.  Somatostatin adjunctive therapy for non-variceal upper gastrointestinal rebleeding after endoscopic therapy.

Authors:  Cheol Woong Choi; Dae Hwan Kang; Hyung Wook Kim; Su Bum Park; Kee Tae Park; Gwang Ha Kim; Geun Am Song; Mong Cho
Journal:  World J Gastroenterol       Date:  2011-08-07       Impact factor: 5.742

2.  Acute propranolol administration effectively decreases portal pressure in patients with TIPS dysfunction. Transjugular intrahepatic portosystemic shunt.

Authors:  L Bellis; E Moitinho; J G Abraldes; M Graupera; J C García-Pagán; J Rodés; J Bosch
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 3.  Emergency sclerotherapy versus vasoactive drugs for bleeding oesophageal varices in cirrhotic patients.

Authors:  Gennaro D'Amico; Luigi Pagliaro; Giada Pietrosi; Ilaria Tarantino
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

4.  Acute esophageal variceal bleeding: Current strategies and new perspectives.

Authors:  Salvador Augustin; Antonio González; Joan Genescà
Journal:  World J Hepatol       Date:  2010-07-27

5.  Hemodynamic effects of propranolol with spironolactone in patients with variceal bleeds: a randomized controlled trial.

Authors:  Binay-K De; Deep Dutta; Rimi Som; Pranab-K Biswas; Subrata-K Pal; Anirban Biswas
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

6.  Endothelial nitric oxide synthase is a critical factor in experimental liver fibrosis.

Authors:  Tung-Ming Leung; George L Tipoe; Emily C Liong; Thomas Y H Lau; Man-Lung Fung; Amin A Nanji
Journal:  Int J Exp Pathol       Date:  2008-04-21       Impact factor: 1.925

7.  Pathophysiology of portal hypertension and esophageal varices.

Authors:  Hitoshi Maruyama; Osamu Yokosuka
Journal:  Int J Hepatol       Date:  2012-05-15

Review 8.  Beta-blockers in liver cirrhosis.

Authors:  Valerio Giannelli; Barbara Lattanzi; Ulrich Thalheimer; Manuela Merli
Journal:  Ann Gastroenterol       Date:  2014

9.  Successful treatment of protein-losing enteropathy induced by intestinal lymphangiectasia in a liver cirrhosis patient with octreotide: a case report.

Authors:  Hang Lak Lee; Dong Soo Han; Jin Bae Kim; Yong Chul Jeon; Joo Hyun Sohn; Joon Soo Hahm
Journal:  J Korean Med Sci       Date:  2004-06       Impact factor: 2.153

Review 10.  Gastrointestinal Bleeding in Cirrhotic Patients with Portal Hypertension.

Authors:  Erwin Biecker
Journal:  ISRN Hepatol       Date:  2013-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.